



SOS for Kids with Eczema

Help us end inequity in access to effective treatment

A guide for healthcare professionals

The Pharmaceutical Benefits Advisory Committee (PBAC) seeks your input on whether dupilumab (brand name Dupixent®) should be funded through the Pharmaceutical Benefits Scheme (PBS) for Australian children aged six months to 11 years with severe eczema.

We know that effective treatment in early life can change the trajectory of a child's life, not only improving control of eczema over the long term, but also reducing their risk of related conditions, including asthma, allergies and hay fever.

Dupilumab has been available through the PBS for adolescents and adults since 2021. It is the only biologic therapy currently TGA-approved for use in young children, but these patients are still waiting for affordable access.



Eczema Support Australia has launched SOS for Kids with Eczema. Help us end the delay in access to dupilumab for Australian children.

What you can do

The PBAC welcomes input on the importance of affordable access to new medicines. This includes insights from healthcare professionals involved in the care of patients who may benefit from the medicine under review.

Whether you are a dermatologist, immunologist, paediatrician, GP, nurse or other medical professional with experience treating or caring for children with severe eczema, your knowledge and insights will be valuable to the PBAC as it considers PBS funding for dupilumab in July.

You can provide your input by completing an online questionnaire via the PBAC portal. It will only take a few minutes of your time. When completing the form, you may wish to highlight:

- The burden of severe eczema on children and their families
- Healthcare system costs, including repeat hospital admissions
- Limitations of current treatment options
- Your experience using dupilumab to treat severe eczema

Have your say before 20 May

- Visit ohta-consultations.health.gov.au/ohta/pbac-july-2026/
- **Click on the link** at the bottom of the webpage to begin.
- **Select** “DUPILUMAB - Dupixent®: Chronic severe atopic dermatitis” from the drop-down menu.

Together, we can end the delay in access to effective treatment for Australian children with severe eczema!



Eczema Support
AUSTRALIA

The trusted source of information, connection and advocacy for Australians living with eczema.
eczemasupport.org.au | 1300 329 362 | contact@eczemasupport.org.au